Fig. 2

Effect of nivolumab treatment on levels of peripheral blood CD8⁺ cells, and their expression of immune mediators. Patient blood samples were collected prior to onset of nivolumab treatment and upon completion of treatment. PBMC were immunostained with antibodies to CD4, CD8, IFN-γ and granzyme B (GranzB), and then analyzed by flow cytometry using the shown gating strategy (a). To quantitate the proportion of CD8⁺CD4⁻ cells (a and b), the analysis first gated on lymphoid cells. The CD8⁺CD4⁻ population was gated on to determine the proportion of CD8⁺ cells that expressed IFN-γ (a and c) or granzyme B (a and d). Each line color in panels b-d indicates the same patient across all panels